MedTrace Logo

Effects of Seaweeds Combined With Probiotics on Intestinal Function of Healthy Subjects

NCT01651741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-09-24

No results posted yet for this study

Summary

The aims of this study are to investigate the effect of seaweeds which is one of the main ingredients of Korean traditional food 'Kimchi' and probiotics on intestinal function of healthy subjects.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Seaweed and Duolac7S

Seaweed and probiotics is composed of seaweed and Duolac7S. Seaweed: 1. Form: brown granule 2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal) 3. Duration: 4 weeks of treatment period Duolac7S: 1. The probiotics, Duolac7S, consist of 7 bacteria. 2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. 3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal) 4. Duration: 4 weeks of treatment period

DIETARY_SUPPLEMENT

Seaweed and Duolac7S-P

Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S). Seaweed: 1. Form: brown granule 2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal) 3. Duration: 4 weeks of treatment period Duolac7S-P: Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).

Sponsors & Collaborators

  • Korea Institute of Planning & Evalution for Technology of Food, Agriculture, Forestry & Fisherie

    lead OTHER

Principal Investigators

  • Jae-Woo Park, KMD, PhD · Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01651741 on ClinicalTrials.gov